Tempero Bio
Financing Round
- Series B
Round Led or Co-led By SymBiosis
Tempero Bio is a clinical-stage biopharmaceutical company committed to advancing innovative treatments for substance use disorders, including alcohol, cocaine, and opioid addiction. Their lead therapeutic candidate, TMP-301, is designed to regulate glutamate signaling in the brain, offering new hope for patients facing addiction.
